Global Antithrombin Market is Projected to Surpass USD 923.4 Million By the End of 2030 with a Growing CAGR of 5.78% | Infinium Global Research

Infinium Global Research, a leading market research company, has recently published a detailed and insightful market research report on the Global Antithrombin Market. This comprehensive report provides an in-depth analysis of various segments and sub-segments within the global and regional Antithrombin market, shedding light on the impact of drivers, restraints, and macro indicators that affect the market both in the short term and long term. The global antithrombin market was valued at USD 593.0 Million in 2022 and is expected to reach USD 923.4 Million by 2030 and grow at a CAGR of 5.78% over the forecast period.

To Know More Request a Sample of this Report: https://www.infiniumglobalresearch.com/reports/sample-request/1258

The global Antithrombin market is projected to grow at a Compound Annual Growth Rate (CAGR) of 5.78% between 2023 and 2030 in terms of value. This growth is primarily driven by the increasing incidence of hereditary and acquired Antithrombin deficiency. Hereditary Antithrombin deficiency is a thrombogenic disorder associated with a 50-90% lifetime risk of venous thromboembolism. Antithrombin plays a critical role in the treatment and diagnosis of hereditary and acquired Antithrombin deficiency, leading to a surge in demand as prevalence increases along with a growing population. Additionally, the expanding use of Antithrombin-based anticoagulants in the pharmaceutical sector is expected to further fuel market demand.

However, the high cost of Antithrombin-based therapies may pose a challenge to market growth. Antithrombin is a more expensive treatment compared to other therapies such as Fresh Frozen Plasma (FFP), leading to a shift in preference towards alternative treatments. Nonetheless, the development of novel recombinant Antithrombin is anticipated to open new opportunities for Antithrombin manufacturers, offering a safer and more abundant supply of this crucial therapeutic.

Leading players in the global antithrombin market include Scripps Laboratories, Inc., Diapharma Group, Inc., Lee Biosolutions, Inc., Dem ilac, Inc., Octapharma AG, Kedrion S.p.A., CSL Limited, Shire Plc, Grifols, and rEVO Biologics, Inc.

The prevalence of symptomatic hereditary Antithrombin deficiency is estimated at between 1 in 2,000 and 1 in 5,000 in the general population, and it is even higher in patients who develop thrombosis. Additionally, acquired Antithrombin deficiency is on the rise due to the increasing prevalence of liver disease and nephrotic syndrome, and premature neonates are at an increased risk of acquired hereditary Antithrombin deficiency. The use of Antithrombin in the treatment and diagnosis of these deficiencies is expected to drive its demand as the prevalence continues to rise along with the global population.

Coronary heart disease (CHD) is a leading cause of mortality worldwide, and the complications of atherosclerosis, such as acute coronary syndrome and ischemic stroke, can be fatal. Antithrombin-based anticoagulants, including Clopidogrel, have played a significant role in expanding the Antithrombin market. The pharmaceutical industry has made substantial efforts to develop antithrombotics that inhibit key enzymes in the coagulation system, further boosting the market.

Despite the promising growth prospects, the cost associated with Antithrombin administration is a practical concern. Cheaper alternatives or supplements may become preferable due to the higher treatment cost, particularly in developing countries. However, increasing awareness of the benefits of Antithrombin in speeding up treatment and reducing hospital costs is expected to drive its demand in the coming years. Moreover, research and development efforts have made it possible to reconstitute Antithrombin for quick administration, further facilitating its use in various clinical applications.

Antithrombin therapy (AT) is being explored for various medical applications, and advances in genetics and biotechnology have enabled large-scale production of human recombinant Antithrombin (rhAT). The safety advantages of rhAT over phAT, such as the avoidance of infection transmission, make it a promising adjuvant in organ transplantation and open doors to new disease indications. These emerging research-based applications are poised to drive growth in the Antithrombin market in the coming years.

Enquire Here Get Customization & Check the Discount for the Report @ https://www.infiniumglobalresearch.com/reports/customization/1258

Table of Content

Chapter 1. Preface

1.1. Report Description

1.2. Research Methods

1.3. Research Approaches

Chapter 2. Executive Summary

Chapter 3. Global Antithrombin Market Overview

3.1. Introduction

3.2. Market Dynamics

3.2.1. Drivers

3.2.2. Restraints

3.2.3. Opportunities

3.3. Porter's Five Forces Analysis

3.4. IGR-Growth Matrix Analysis

3.5. Competitive Landscape in the Global Antithrombin Market

Chapter 4. Global Antithrombin Market by Application

4.1. Therapeutics

4.2. Research and Diagnostics

Chapter 5. Global Antithrombin Market by Source

5.1. Human

5.2. Goat Milk

Chapter 6. Global Antithrombin Market by Formulation

6.1. Lyophilized

6.2. Liquid

Chapter 7. Global Antithrombin Market by Region 2023-2030

7.1. North America

7.1.1. North America Antithrombin Market by Application

7.1.2. North America Antithrombin Market by Source

7.1.3. North America Antithrombin Market by Formulation

7.1.4. North America Antithrombin Market by Country

7.2. Europe

7.2.1. Europe Antithrombin Market by Application

7.2.2. Europe Antithrombin Market by Source

7.2.3. Europe Antithrombin Market by Formulation

7.2.4. Europe Antithrombin Market by Country

7.3. Asia-Pacific

7.3.1. Asia-Pacific Antithrombin Market by Application

7.3.2. Asia-Pacific Antithrombin Market by Source

7.3.3. Asia-Pacific Antithrombin Market by Formulation

7.3.4. Asia-Pacific Antithrombin Market by Country

7.4. RoW

7.4.1. RoW Antithrombin Market by Application

7.4.2. RoW Antithrombin Market by Source

7.4.3. RoW Antithrombin Market by Formulation

7.4.4. RoW Antithrombin Market by Sub-region

Chapter 8. Company Covered

8.1. Scripps Laboratories, Inc.

8.2. Diapharma Group, Inc.

8.3. Lee Biosolutions, Inc

8.4. Dem ilac, Inc

8.5. Octapharma AG

8.6. Kedrion S.p.A.

8.7. CSL Limited

8.8. Shire Plc

8.9. Grifols

8.10. rEVO Biologics, Inc.

More Insights on this report, Speak to Our Analyst: https://www.infiniumglobalresearch.com/reports/enquiry/1258

Reasons to Buy this Report:

=> Comprehensive analysis of global as well as regional markets of antithrombin.

=> Complete coverage of all the product types and application segments to analyze the trends, developments, and forecast of market size up to 2030.

=> Comprehensive analysis of the companies operating in this market. The company profile includes an analysis of the product portfolio, revenue, SWOT analysis, and the latest developments of the company.

=> Infinium Global Research- Growth Matrix presents an analysis of the product segments and geographies that market players should focus on to invest, consolidate, expand, and/or diversify.

2nd Floor, Ganadish Empire, Rahatani Chowk, Pimple Saudagar, Pimpri-Chinchwad, Maharashtra 411027

About Infinium Global Research:

Infinium Global Research is a business consulting and market research firm; a group of experts that caters to fulfilling the business and market research needs of leading companies in various industry verticals and business segments. The company also serves government bodies, institutes, and non-profit/non-government organizations to meet their knowledge and information needs.
Through our information services and solutions, we assist our clients to improve their performance and assess the market conditions to achieve their organizational goals. Our team of experts and analysts are engaged in continuously monitoring and assessing the market conditions to provide knowledge support to our clients. To help our clients and to stay updated with the advances and inventions in technology, business processes, regulations, and the environment, Infinium often conducts regular meetings with industry experts and opinion leaders. Our key opinion leaders are involved in monitoring and assessing the progress in the business environment, so as to offer the best opinion to our clients.

This release was published on openPR.